- Investing Ideas
- /
- Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
7
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
7 companies
Biocon
Market Cap: ₹511.2b
Manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally.
BIOCON
₹383.10
7D
-2.8%
1Y
7.6%
Orchid Pharma
Market Cap: ₹39.4b
A pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.
ORCHPHARMA
₹777.40
7D
9.4%
1Y
-45.2%
Indoco Remedies
Market Cap: ₹28.5b
Manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally.
INDOCO
₹309.35
7D
-2.5%
1Y
-5.0%
Jenburkt Pharmaceuticals
Market Cap: ₹5.6b
Researches and develops, manufactures, and markets pharmaceutical and healthcare products in India.
524731
₹1,278.60
7D
-3.3%
1Y
40.4%
SMS Lifesciences India
Market Cap: ₹3.3b
Manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.
SMSLIFE
₹1,092.50
7D
-8.0%
1Y
13.6%
Bacil Pharma
Market Cap: ₹539.4m
Manufactures, exports, and retails pharmaceuticals, medicinal chemicals, and botanical products in India.
524516
₹37.58
7D
5.0%
1Y
89.6%
Gujarat Terce Laboratories
Market Cap: ₹364.7m
Develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally.
524314
₹49.15
7D
-1.1%
1Y
5.6%